Olema Pharmaceuticals (OLMA) Non Operating Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Non Operating Income data on file, last reported at $4.9 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 9.21% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $16.7 million, a 19.86% increase from a year earlier, with the FY2025 full-year figure at $16.2 million, up 27.09% from the prior year.
• Non Operating Income for Q1 2026 stood at $4.9 million, up from $4.0 million in the prior quarter.
• Over the last five years, Non Operating Income for OLMA reached as high as $4.9 million in Q1 2026 and fell as low as $224000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $2.6 million across 5 years, with a median of $3.1 million in 2024.
• Across the five-year window, Non Operating Income soared 924.49% in 2022 and retreated 12.16% in 2024, its largest moves.
• Year by year, Non Operating Income stood at $1.0 million in 2022, then jumped by 250.38% to $3.6 million in 2023, then slipped by 12.16% to $3.2 million in 2024, then gained by 25.68% to $4.0 million in 2025, then advanced by 21.73% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $4.9 million in Q1 2026, $4.0 million in Q4 2025, and $3.7 million in Q3 2025.